OverviewSuggest Edit

Translate Bio develops medicines to treat diseases caused by protein or gene dysfunction. It uses single-stranded oligonucleotides to target the repressive interactions of long non-coding RNA (lncRNA) with specific genes of interest, thereby upregulating mRNA and increasing expression of the encoded protein. The Company is applying its proprietary technology to develop new treatments in several therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, oncology, metabolic diseases and neurodegenerative diseases.
TypePublic
Founded2011
HQLexington, US
Websitetranslate.bio

Latest Updates

Employees (est.) (Dec 2018)81(+33%)
Job Openings19
Share Price (Oct 2019)$8.1 (-9%)

Key People/Management at Translate Bio

Ronald C. Renaud

Ronald C. Renaud

CEO
John Schroer

John Schroer

CFO
Ann Barbier

Ann Barbier

Chief Medical Officer
Brian Fenton

Brian Fenton

Chief Business Officer
Michael Heartlein

Michael Heartlein

Chief Scientific Officer
Paul Burgess

Paul Burgess

General Counsel
Show more

Translate Bio Office Locations

Translate Bio has an office in Lexington
Lexington, US (HQ)
29 Hartwell Ave
Show all (1)

Translate Bio Financials and Metrics

Translate Bio Revenue

USD

Net income (Q2, 2019)

(27.8m)

EBIT (Q2, 2019)

(28.2m)

Market capitalization (11-Oct-2019)

486.7m

Closing stock price (11-Oct-2019)

8.1

Cash (30-Jun-2019)

74.9m
Translate Bio's current market capitalization is $486.7 m.
Annual
USDFY, 2016FY, 2017FY, 2018

General and administrative expense

11.1m14.3m22.6m

R&D expense

15.7m47.0m58.0m

Operating expense total

26.8m79.2m105.7m

EBIT

(26.8m)(79.2m)(104.2m)
Quarterly
USDQ1, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

General and administrative expense

3.0m4.8m6.0m6.0m6.6m7.9m

R&D expense

9.6m12.7m15.2m12.9m17.4m16.6m

Operating expense total

14.9m22.4m29.1m45.7m35.7m29.4m

EBIT

(14.9m)(22.4m)(29.1m)(45.5m)(34.2m)(28.2m)
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

57.7m48.1m55.2m

Prepaid Expenses

685.0k3.0m

Current Assets

205.6m198.5m149.6m

PP&E

4.9m6.8m10.2m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

30.8m16.5m38.9m62.4m74.9m

Prepaid Expenses

4.3m

Current Assets

182.8m24.3m166.3m128.9m153.9m

PP&E

9.2m9.9m10.1m10.8m10.9m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(26.7m)(66.4m)(97.4m)

Depreciation and Amortization

730.0k1.6m2.8m

Accounts Payable

84.0k4.0m658.0k

Cash From Operating Activities

(23.7m)(50.8m)(22.1m)
Quarterly
USDQ1, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(14.0m)(21.2m)(48.7m)(91.4m)(33.2m)(61.0m)

Depreciation and Amortization

191.0k536.0k1.4m1.9m1.0m2.0m

Accounts Payable

698.0k1.5m1.1m(1.6m)(1.0m)(1.9m)

Cash From Operating Activities

(9.6m)(16.9m)(33.6m)(5.9m)(21.5m)(41.4m)
USDY, 2019

Financial Leverage

2.6 x
Show all financial metrics

Translate Bio Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Translate Bio MA
Translate Bio Securities Corporation

Translate Bio Online and Social Media Presence

Embed Graph

Translate Bio News and Updates

Translate Bio Announces Upcoming MRT5005 Presentations at the 33rd Annual North American Cystic Fibrosis Conference

LEXINGTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced upcoming oral and pos…

Translate Bio to Present at the 3rd Annual Chardan Genetic Medicines Conference

LEXINGTON, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Ronald Re…

Translate Bio Announces Pricing of Public Offering of Common Stock

LEXINGTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the pricing of…

Translate Bio to Present at the Jefferies 2019 Healthcare Conference

LEXINGTON, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Ronald Rena…

Translate Bio Announces First Quarter 2019 Financial Results and Provides Corporate Update

-- Completed dosing in single-ascending dose portion of Phase 1/2 clinical trial in cystic fibrosis; data expected 3Q19 -- LEXINGTON, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potential…

Translate Bio Announces $47.5 Million Private Placement

LEXINGTON, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, announced today that it has ente…
Show more

Translate Bio Frequently Asked Questions

  • When was Translate Bio founded?

    Translate Bio was founded in 2011.

  • Who are Translate Bio key executives?

    Translate Bio's key executives are Ronald C. Renaud, John Schroer and Ann Barbier.

  • How many employees does Translate Bio have?

    Translate Bio has 81 employees.

  • Who are Translate Bio competitors?

    Competitors of Translate Bio include Freenome, Proteus Digital Health and Human Longevity.

  • Where is Translate Bio headquarters?

    Translate Bio headquarters is located at 29 Hartwell Ave, Lexington.

  • Where are Translate Bio offices?

    Translate Bio has an office in Lexington.

  • How many offices does Translate Bio have?

    Translate Bio has 1 office.